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Abstract  
 
Monoamine oxidases (MAO) influence the monoamine levels in brain by virtue of their 
role in neurotransmitter breakdown. MAO B is the predominant form in glial cells and in 
platelets. MAO B structure, function and kinetics are described as a background for the 
effect of alterations in its activity on behavior. The need to inhibit MAO B to combat 
decreased brain amines continues to drive the search for new drugs. Reversible and 
irreversible inhibitors are now designed using data-mining, computational screening, 
docking and molecular dynamics. Multi-target ligands designed to combat the elevated 
activity of MAO B in Alzheimer’s and Parkinson’s Diseases incorporate MAO inhibition 
(usually irreversible) as well as iron chelation, antioxidant or neuroprotective properties. 
The main focus of drug design is the catalytic activity of MAO, but the imidazoline I2 site in 
the entrance cavity of MAO B is also a pharmacological target. Endogenous regulation of 
MAO B expression is discussed briefly in light of new studies measuring mRNA, protein, or 
activity in healthy and degenerative samples, including the effect of DNA methylation on 
the expression. Overall, this review focuses on examples of recent research on the 
molecular aspects of the expression, activity, and inhibition of MAO B. 
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1. Introduction 
 
The monoamine neurotransmitters dopamine, serotonin, and noradrenaline influence 
neuronal signaling in the brain. Changes in the monoamine system are associated with 
depression, addiction, aggression, and amine levels decrease in neurodegenerative 
diseases. 
 
The balance between the synthetic enzymes and the breakdown enzymes sets the 
overall level of amines in the brain. The amount of the neurotransmitter amines available 
for signaling is strongly dependent upon the reuptake carriers (DAT, SERT, NET) and on 
the vesicular transporter (VMAT) driven by the proton gradient generated by the vesicular 
ATPase. Neurotransmitter release is controlled by signaling pathways and modulated by 
pre-synaptic auto-receptors. The post-synaptic effect of the neurotransmitters depends on 
specific families of receptors (D1-5 5-HT1-7 and adrenergic receptors, and the related 
TAAR1 for trace amines), most of which are G-protein coupled receptors (GPCRs) – see 
(Beaulieu et al., 2015, McCorvy and Roth, 2015), and the IUPHAR database of the genetic 
and functional properties of receptors (http://www.guidetopharmacology.org/) (Sharman et 
al., 2011).  
 
MAO, as the major metabolic enzyme for the deactivation of the monoamine 
neurotransmitters, is a key target in neuro-psychopharmacology. Its inhibitors, used as 
antidepressant drugs for over 50 years, have been shown to raise brain amine levels. The 
observation that inhibition of MAO increases monoaminergic function has supported a 
long-running drug discovery effort to find novel drugs that inhibit MAO to treat mood and 
degenerative disorders, including depression, aggression, schizophrenia, hyperactivity, 
Parkinson’s Disease (PD), and Alzheimer’s Disease (AD) (Oreland, 2004, Murphy et al., 
2006, Oreland et al., 2007, Fisar et al., 2010, Bortolato and Shih, 2011, Song et al., 2013). 
In current efforts to discover compounds to combat neurodegeneration in PD and AD, 
MAO inhibition is a key feature in multi-target designed ligands (MTDL) that are intended 
to help spare the decreasing levels of neurotransmitters (Ramsay, 2012, Zheng et al., 
2012, Bautista-Aguilera et al., 2014). A further benefit of inhibiting MAO is the decreased 
production of ammonia and hydrogen peroxide that accompany amine oxidation, thus 
reducing oxidative stress (Kaludercic et al., 2014, Ooi et al., 2015). 
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MAO iso-enzymes are important because their activity sets the monoaminergic tone of 
the brain. The interest in drug design to increase monoamine levels is reflected in a 
constant stream of reviews. Several reviews in the last 5 years provide the wider 
background to MAO (Bortolato and Shih, 2011, Youdim and Reiderer, 2011, Ramsay, 
2012, Song et al., 2013, Fowler et al., 2015) This review will include key references for the 
established facts but focus on examples of recent research on the expression, activity and 
inhibition of MAO B. 
 
2.  MAO influences the monoamine levels in brain 
 
2.1 Lower MAO activity means higher amine levels and vice versa 
 
That low MAO activity is associated with higher amines has been demonstrated in 
knockout mice (or MAO-deficient humans) and in both animals and humans after inhibitor 
treatment. MAOA/B knockout mice displaying anxiety-like symptoms have greatly elevated 
monoamine levels (Chen et al., 2004). Humans lacking MAO B have greatly elevated 
levels of phenylethylamine (Murphy et al., 1990). In rats, numerous microdialysis 
experiments have been conducted to measure amine changes in different disease models 
(including addiction) or to assess the effects of MAO inhibitors (for example, (Butcher et 
al., 1990, Lamensdorf et al., 1996, Gal et al., 2005, Bazzu et al., 2013, Sader-Mazbar et 
al., 2013, Bolea et al., 2014)). After treatment with MAO inhibitor, mice showed 
significantly higher noradrenaline and serotonin levels and significantly lower metabolites 
(including DOPAC from dopamine) (Lum and Stahl, 2012). 
   
In human brain, MAO A levels measured by [C11]-clorgyline binding in PET scans 
showed a clear elevation of activity associated with depression (Meyer et al., 2006). Other 
studies have examined the changes in metabolites associated with polymorphisms 
confirming that higher activity alleles show more metabolism of dopamine, noradrenaline 
and serotonin (Aklillu et al., 2009, Andreou et al., 2014).  Elevated MAO activity had 
already been observed in AD-type dementia in 1980 (Adolfsson et al., 1980). Later work 
has established that it is MAO B activity that increases with age in human brain 
(associated with gliosis) and is elevated in several degenerative diseases. Recently, a 
range of experimental techniques have been used to demonstrate increased MAO B 
activity in Huntington’s, Alzheimer’s and Parkinson’s diseases (Kennedy et al., 2003, 
Zellner et al., 2012, Woodard et al., 2014, Ooi et al., 2015).  For example, in a new 
	 5	
approach, genes related to the dopaminergic system were studied in iPSC neurons from 
twins without and with PD. Genes for the dopamine receptors and for dopamine synthesis, 
uptake, release, and metabolism were found to be differentially expressed in PD neurons 
compared to those from the identical twin (Woodard et al., 2014). MAO B was higher by 
almost 1.5-fold in both of the PD-affected persons compared to their unaffected twin. 
 
2.2  MAO inhibition raises brain amine levels 
 
2.2.1 Animal – microdialysis.    As noted above, microdialysis has been used to 
demonstrate changes in amine levels in the brain. Improved methods enable more 
sophisticated experimental design and analysis. The improvement in the separation and 
quantification of the monoamines and their metabolites (De Benedetto et al., 2014), with 
excellent temporal resolution (1min (Gu et al., 2015)), and combination with 
electrophysiology (Flik et al., 2015) has brought direct measurements of brain amines in 
disease models or in response to drugs into standard practice. In combination with 
behavioural studies, microdialysis is a very useful experimental tool for the 
characterization of new models, such as birds (Ihle et al., 2015), that will lead to better 
understanding of the influences of monoamines on behavior. In another example, MAO B 
inhibition has long been used as an adjunct to DOPA therapy for PD to spare dopamine by 
decreasing its metabolism. Microdialysis in rats has confirmed that deprenyl treatment 
results in higher dopamine levels for longer (Malmlof et al., 2015). 
  
2.2.2 Human studies.  In order to see elevation of brain amines in humans, more 
than 90% inhibition of MAO is required (Fowler et al., 2015). The altered amine balance as 
a result of MAO inhibition then initiates a process of change in the CNS, with a lag of 
around three weeks before effects on mood are detected. Conversely, most of the MAO 
inhibitors in common use are irreversible inhibitors so recovery from inhibition is slow 
(Fowler et al., 1996, Zajecka and Zajecka, 2014). It should be noted that, although PET 
scans are the method of choice for measuring the levels of active MAO in the brain, the 
method does not measure changes in the brain amines (Fowler et al., 2015). 
 
Human urinary metabolites have given insight into amine metabolism in humans since 
the 1970s. Analysis of urine samples was used to identify perturbed amine metabolism in 
males with abnormal behavior due to a terminating point mutation in the MAO A gene 
(Brunner et al., 1993). Interestingly, the urinary metabolites for MAO A and MAO B 
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deficiencies gave distinctly different patterns. In humans lacking MAO A, deaminated 
catecholamines decreased and O-methylated metabolites increased. In contrast, men with 
the MAO B gene deletion excrete phenylethylamine, a trace amine normally metabolised 
by MAO B (Lenders et al., 1996). 
 
Human plasma levels of metabolites are higher than those in urine but follow similar 
trends (see for example  (Hyland, 2008, Mercimek-Mahmutoglu et al., 2014). 
Pharmacokinetic assessment of MAO B inhibitors routinely measured metabolites in 
plasma and MAO B inhibition in platelets (Dingemanse et al., 1996).  
 
Although use of human cerebrospinal fluid (CSF) is more invasive for the patient, 
measurement of neurotransmitters and their metabolites in CSF is considered to give the 
most direct insight into the brain levels (Hyland, 2008). However, large inter-individual 
variations (Dhondt and Forzy, 2003) mean that comparative measurements during 
treatment are more useful than single values. One example, a study on the effects of the 
irreversible MAO inhibitor called F70, demonstrated that dopamine and serotonin were 
raised as a consequence of the treatment, and the metabolites were significantly lower 
(Moron et al., 2000).  
 
Serotonin toxicity events provide strong evidence for raised amine levels in humans. 
The clinical symptoms of serotonin toxicity arise when MAO inhibitors (especially non-
selective or MAO A inhibitors) are administered in patients already taking serotonin 
reuptake inhibitors (SSRIs) (Gillman, 2011).  
 
2.3 MAO inhibition decreases the toxic by-products of MAO activity 
 
 MAO activity generates H2O2 that can damage molecules in nearby parts of the cell. 
Tyramine added to isolated mitochondria increased the production of H2O2 by 1.6 
nmol/min/mg protein, and more than doubled the single-strand breaks in mitochondrial 
DNA (Hauptmann et al., 1996). Inhibition of MAO in rat brain by rasagiline (MAO B 
specific) or clorgyline (MAO A specific) decreased lipid peroxidation by half (Aluf et al., 
2013). Chronic rasagiline treatment also increased defenses against oxidative stress as a 
consequence of the up-regulated expression of BDNF, Bcl-2 and catalase in the brains of 
aged mice (Weinreb et al., 2015). 
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The oxidative stress arising from H2O2 generated by MAO activity is likely to be higher 
in glial cells than in neurons.  In neurons, the vesicular reuptake competes for amine 
molecules with MAO A (or MAO B in serotonergic neurons). Although amine penetration 
into glial cells is less, all amine molecules are available for oxidation by MAO. It can be 
speculated that in the presence of SSRIs, oxidative stress would increase due to 
increased diffusion of amines from the synaptic cleft. In the periphery, platelet MAO B 
oxidises the serotonin very slowly, but any other amines penetrating the platelet will 
contribute to H2O2 generation. The contribution of amines to oxidative stress significant to 
physiology has been studied in heart and attributed to MAO A in the cardiomyocytes. 
Activated platelets release serotonin during cardiac ischemia, some of which is taken up 
by amine transporters into the cardiomyocytes. After reperfusion, serotonin is metabolised 
by MAO A generating H2O2. Damage and cardiomyocyte apoptosis can be prevented by 
inhibition of the amine transporter or MAO, or by antioxidants (Bianchi et al., 2005). 
Studies in this area since 2002 when the importance of amine plus MAO-generated 
oxidative stress became apparent, and some insights into the mechanisms involved are 
reviewed in (Kaludercic et al., 2014).  More recently, MAO has been noted as a source of 
oxidative stress in diabetes (Sturza et al., 2015). These associations expand the 
application of MAOI to heart disease and vascular damage as reviewed in (Deftereos et 
al., 2012).  
 
 
3. Monoamine Oxidase B expression 
 
3.1  Regulation	of	MAO	B	expression		 
 
MAO A and B genes have identical exon-intron organization but are regulated 
differently (reviewed in (Shih and Chen, 2004)). Both promoters are GC-rich and regulated 
by transcription factor Sp1, but the Sp1 sites are organized differently. The promoter 
organization and transcriptional regulation for MAO B are summarized in Fig. 1. MAO B 
expression is up-regulated by decreased methylation, as observed in smokers (Launay et 
al., 2009). This was tested and confirmed in HeLa cells incubated with a DNA 
methyltransferase inhibitor resulting in decreased methylation of the MAO B promoter and 
increased MAO B expression (Wong et al., 2003). MAO B expression is also modulated by 
retinoic acid, by glucocorticoids and by the sex steroids (reviewed in (Shih et al., 2011).  
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Fig. 1. Promotor and transcriptional regulation of MAO B (adapted from (Shih et al., 2011). 
 
 
3.2   Human genetic and epigenetic variations 
 
Complete lack of MAO A and MAO B was discovered in Norrie’s disease where part of 
the X chromosome is deleted. The affected males have no MAO B activity in platelets and 
marked changes in the amine metabolites (Murphy et al., 1990). Subsequently, males with 
micro-deletions were identified, revealing that MAO A deletion has a strong influence on 
both amine metabolism and behavior, whereas those with the MAO B micro-deletion 
showed neither mental retardation nor abnormal behavior.   The biggest change in the 
absence of MAO B is the excretion of large quantities of PEA (Lenders et al., 1996, Shih et 
al., 1999).  
  
Genetic studies have identified polymorphisms that affect expression levels of MAO, the 
main reason for higher or lower MAO activity in individuals (Manuck et al., 2000, 
Balciuniene et al., 2002) leading to many clinical studies relating behavior to MAO status. 
Large numbers of genetic studies have looked for polymorphisms in MAO B that are 
different in control and experimental groups with altered behavior. Only one polymorphism 
in MAO B affects activity: a single nucleotide alteration (A644G in intron 13 of the MAO B 
gene) results in lower enzyme activity and increased levels of synaptic monoamine 
concentrations. Whether using genetics or platelet activity measurements, low MAO B 
activity results in behavioral disinhibition, risky behaviour, and poor impulse control (for 
reviews see (Oreland and Hallman, 1995, Bortolato et al., 2009). Studies looking for  
association of the A644G polymorphism with depression, schizophrenia, autism, or 
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addictions have produced mixed results. A recent meta-analysis of twenty studies with 
2846 patients and 3508 controls provides evidence for a slightly increased risk of PD with 
the G allele (Liu et al., 2014). The A allele is associated with slightly lower platelet MAO B 
activity (Garpenstrand et al., 2000), so the meta-analysis is consistent with the observation 
of the lower incidence of PD in smokers where MAO B is inhibited. 
 
 Epigenetics can play a role in determining the level of MAO activity expressed, as 
indicated by a study comparing the methylation state of the MAO A gene with the brain 
MAO A activity in men (Shumay et al., 2012). Increase methylation on MAO A, MAO B and 
COMT genes was found in borderline personality disorder but activity was not measured 
(Dammann et al., 2011).  
 
3.3 Expressed protein levels  
 
MAO B is highly expressed in liver and is the predominant form of MAO in platelets, 
glial cells and serotonergic neurons. Note that rats, mice and humans have slightly 
different distribution of the MAO isoenzymes (Youdim and Finberg, 1983). MAO B is low in 
the neonate both in mice and humans, but increases rapidly after birth (Holschneider et 
al., 2001, Nicotra et al., 2004).   
 
Many studies have used platelets to establish associations between MAO B and 
neuropathologies or behavioural aberations, measuring mRNA, protein or activity. (Note 
that these measurements may or may not correlate with each other, so cannot be used 
interchangeably.) Levels of MAO B in platelets at least indicate the genetically determined 
expression levels in brain. The premise is sufficiently established to allow a platelet protein 
biochip, developed for detection of an Alzheimer's disease-specific phenotype, to include 
MAO B (Veitinger et al., 2014a, Veitinger et al., 2014b). This technical advance in 
diagnosis could be expanded for other neuropathologies or behavior with known 
associations to MAO B, for example, alcoholism (Coccini et al., 2002).  
 
Although platelets are a convenient source for measurement of MAO B as a biomarker, 
the best method to examine the levels of MAO A and MAO B in the brain is by Positron 
Emission Tomography (PET). Multiple ligands for MAO A or for MAO B are now available 
and the pharmacokinetics are well understood, as reviewed in (Fowler et al., 2015) . An 
irreversible ligand such as deprenyl requires active MAO B to form the adduct, so serves 
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as an in vivo measurement of both protein and activity; reversible ligands measure only 
protein levels. 
 
 
Fig. 2. MAO B monomer structure. The two views of MAO B were prepared from pdb file 1oja 
using AutoDock. The  bound isatin was removed, the covalent bond between the FAD and Cys 
198 inserted, and hydrogen atoms added. The FAD and the tyrosines that form the aromatic cage 
around the active site are shown as sticks; the general structure is shown in ribbon form. A. Side 
view showing the helix that is buried in the membrane; the active site cavity bounded by FAD and 
three tyrosines is seen in the middle.  B. View looking up from the membrane through the entrance 
cavity to the active site. 
 
4. Molecular properties of MAO B 
 
4.1 MAO B protein: structure, active site and I2 site  
 
MAO B forms a homo-dimer in which each subunit (59000 daltons) contains one 
covalently-bound FAD linked to cysteine 397 (Edmondson et al., 2009). Each monomer 
(Fig. 2) has one helix buried in the mitochondrial outer membrane and further surface area 
thought to associate with the membrane. In the membrane-bound dimer, the distance 
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between the N5 atoms of the two FAD molecules, measured by pulsed dipolar ESR 
spectroscopy after irreversible modification of the FAD with a nitroxide spin-labeled 
irreversible inhibitor, was 4.4 nm (Upadhyay et al., 2008, Edmondson et al., 2009).  
 
In general terms, MAO B has a larger but more restricted binding cavity than does MAO 
A, as described in detail in a comparative review of the structures of the two enzymes 
(Edmondson et al., 2007). In MAO B, two amino acid side chains (Ile199 and Tyr326) form 
a “gate” between the entrance cavity and the catalytic site. The gate is easily opened by 
movement of these side chains, to accommodate large ligands, as seen in the crystal 
structures for MAO B with, for example, deprenyl (2BYB (Binda et al., 2005a)) or ASS234 
(4CRT (Esteban et al., 2014)). It can also be stabilized in the closed position after 
inactivation with tranylcypromine (TCP) (Bonivento et al., 2010, McDonald et al., 2010). 
The closed conformation organizes the entrance cavity of MAO B into a binding site for 
imidazoline ligands of the I2 type. In the crystal structure of TCP-inactivated MAO B, the I2 
ligand (2-BFI) is held in place by the closed gate residues, Ile199 and Tyr326, and by 
Pro102 and Phe99. High affinity (nM) binding to MAO B was first demonstrated using 
various I2 ligands in a small proportion of native human MAO B heterologously expressed 
in yeast (Tesson et al., 1995), and further explored in detailed kinetic and binding 
experiments (McDonald et al., 2010). The kinetic studies demonstrated that binding in the 
entrance cavity I2 site could take place either to free enzyme or when substrate or product 
was bound, giving mixed inhibition patterns. However, the measured Ki for 2-BFI inhibition 
of MAO B activity is in the µM range (49 µM) (Jones et al., 2007)) presumably because 
only a small proportion of MAO B molecules have the correct conformation for the high 
affinity binding. Molecular dynamics looking at mobility of residues 109-112 in the adjacent 
“substrate cavity loop” (residues 99-112 (Binda et al., 2003)) showed that inactivation of 
MAO B with TCP resulted in a stabilization of the loop that was not observed in the free 
enzyme, so the loop may also play a part in the high affinity binding of I2 ligands (Basile et 
al., 2014).  
 
Despite the molecular studies over almost 20 years, interest in drug development for I2 
sites has only recently accelerated with a compound for pain relief entering clinical trials 
(Lanza et al., 2014), although the analgesic effect is unlikely to be due to binding to MAO 
B since I2 ligands bind to multiple sites and the target for this compound is not known. New 
ligands enable detection and imaging studies for distribution and occupancy of I2 sites 
(Tyacke et al., 2012, Kealey et al., 2013, Keller and Garcia-Sevilla, 2015). Further 
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development will be aided by computational methods, both for structure-function 
relationships and for drug-like properties to ensure brain permeation (Moraes and de 
Azevedo, 2012, Nikolic and Agbaba, 2012, Vucicevic et al., 2015). With better 
understanding of the pharmacology of I2 sites, behavioral studies are also now appearing 
(Qiu et al., 2014, Qiu et al., 2015). 
 
4.2 	MAO	B	activity:	catalysis	and	mechanism	
 
4.2.1 The	MAO	B	catalytic	cycle.		The data presented in this section has 
accumulated over two decades, but is reiterated as important background for cellular 
studies and drug design. The key parameters that define enzyme activity are the steady-
state rate constant kcat and the KM values for the substrates. Knowing the mechanism 
followed in the catalytic process is also useful in designing inhibitors. Amine is oxidized to 
the imine with concomitant reduction of the flavin cofactor. The reduced flavin is reoxidized 
by oxygen, producing H2O2. The imine is non-enzymically hydrolyzed to give a stable 
aldehyde product. Although this may seem like a simple ping-pong mechanism, the 
oxidative half-reaction is slow, unless a new substrate molecule is bound to the reduced 
MAO, as shown in Fig. 3. The rate constants for the different steps in the reaction are such 
that MAO in either oxidized or reduced form can bind substrate or inhibitor with different 
proportions in each form depending on the substrate. 	
 
Different substrates are oxidized at very different rates. Based on the kinetic parameters 
reviewed in (Youdim et al., 2006, Edmondson et al., 2009, Ramsay et al., 2011), MAO A 
and MAO B are equally efficient at metabolizing dopamine with kcat/KM values greater than 
for other physiological substrates. With serotonin, MAO A is about 40 times better than 
MAO B, whereas with phenylethylamine MAO B is about 35 times better than MAO A, with 
both kcat and KM differences. From these kinetic measurements, it is clear that dopamine 
and noradrenaline are metabolized by both MAO A and MAO B, but serotonin is 
metabolized mainly by MAO A. Since serotonergic neurons contain mainly MAO B, this is 
consistent with a role for the MAO B in serotonergic neurons to protect mitochondria and 
the nerve terminals from other neurotransmitters.  
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Fig. 3. Kinetic cycle of MAO B. The scheme shows two forms of MAO B (E, oxidized and F, 
reduced) both of which can bind substrate (S) or product (P) reversibly. The reduction step (kr) is 
the slowest step. There are three possible forms of the reduced enzyme (FP, F, and FS in red 
square boxes) each of which reacts with oxygen at a different rate (ko, ko’, ko’’) to return to the 
equivalent oxidized form of the enzyme (in blue circles) 
 
4.2.2 Kinetics: kcat, KM amines, KM oxygen.  Most of the early kinetic studies, in 
common with many pharmacological studies, were performed in rats, where it was noted 
that the KM values for the amine substrates varied with the oxygen concentration (Fowler 
and Oreland, 1980). Successful cloning into Pichia pastoris (Newton-Vinson et al., 2000) 
enabled work on human MAO B. It is important to note that the KM value for oxygen is 0.33 
mM for human MAO B (Newton-Vinson et al., 2000), higher than the concentration of 
oxygen in water (0.215 mM at 37 °C). Thus, reoxidation will contribute to the steady-state 
reaction rate for MAO B in air-saturated buffer (McDonald et al., 2010). Any decrease in 
oxygen concentration in the cell will slow amine catabolism by MAO B. 
 
In the steady state, MAO B molecules can be in either oxidized or reduced form (Fig. 3). 
The two forms have different affinities for the substrates (and inhibitors) (Tan and Ramsay, 
1993, McDonald et al., 2010). The complex kinetics mean that the normal medicinal 
chemistry measure for new inhibitors, namely the IC50 value which depends on the 
conditions of the assay used, may not be readily comparable to in vivo conditions. Binding 
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of inhibitor to both oxidized and reduced enzyme (E and F in Fig. 3) was first 
demonstrated for amphetamine (Pearce and Roth, 1985). Using the same principles, high 
throughput assays now can provide sufficient information to determine routinely the Ki 
values for binding of inhibitors to each form (McDonald et al., 2010, Ramsay et al., 2011) 
(see below). The different values obtained for binding to oxidized and reduced MAO will 
influence the observed Ki  in assessments where fewer points are used (see (Ramsay et 
al., 2011). The observed Ki will vary with the substrate used because the differing rate 
constants for each substrate means that the steady-state population of free reduced 
enzyme versus free oxidized enzyme is different for each substrate. The differences in 
steady-state redox balance are apparent in stopped-flow monitored turnover 
spectrophotometry (Tan and Ramsay, 1993) . This means that the in vivo effectiveness of 
a reversible inhibitor is not simple to predict and it will vary by cell type and brain region, 
depending on the most plentiful catecholamine and its concentration.  Where serotonin is 
the main substrate as in serotonergic neurons, MAO B will be mostly oxidized (KM high, 
reduction 17 times slower then oxidation). When phenylethylamine is the main amine 
present, MAO B will be mostly reduced (KM low, reduction 300 times faster than oxidation). 
 
 
4.2.3 Chemical mechanism. From the deuterium isotope effects in steady state and 
stopped-flow monitored pre-steady state kinetic experiments, it is clear that the slowest 
step in the MAO A reaction is the breaking of the bond between hydrogen and the α-
carbon in the amine substrate. In MAO B, the re-oxidation of the reduced MAO B may be 
slower than the bond-breaking step. This is clearly seen in the rate constant for reduction 
of MAO B by phenylethylamine at 543 s-1, 500 times faster than the re-oxidation of 
reduced MAO B (1 s-1) (Ramsay et al., 1987). Nonetheless, a deuterium isotope effect of 
8.2 on turnover (5.3 on kcat/KM) of benzylamine (Walker and Edmondson, 1994) indicates 
that the hydrogen extraction is energetically the most difficult step of the reaction.  
Theoretical calculations for the oxidation of dopamine give an activation free energy (ΔG‡) 
for formation of the transition state of 16.1 kcal mol-1 (Repic et al., 2014) in excellent 
agreement with the experimental value of 16.5 kcal mol-1 (Edmondson et al., 2009). 
 
The controversial question is how two hydrogens are transferred from the amine to the 
flavin. There being no base in the active site protein sequence to accept a proton, there 
are three possible mechanisms for the chemical mechanism of MAO. The polar 
nucleophilic mechanism postulates a transient adduct to the C4a atom of the FAD 
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cofactor, with the N5 then acting as a base to remove the proton. This mechanism is 
supported by quantitative structure-activity relationships for a series of substituted 
benzylamine substrates with MAO B (Walker and Edmondson, 1994). Single electron 
transfer followed by proton transfer is the mechanism well supported by studies on the 
inactivation of MAO by cyclopropylamines (Silverman, 1995) but no radical intermediate 
has been detected during turnover, even with slow substrates. The third mechanism, a 
simple hydride transfer, cannot be ruled out (Kay et al., 2007) but there is no positive 
evidence to support it. Indeed, the temporal separation of the carbon-hydrogen bond 
cleavage from the change in the nitrogen atom required as a consequence of hydride 
transfer (rehybridisation (MacMillar et al., 2011)) does not support a hydride transfer 
mechanism. In a novel approach, a synthetic chemical model successfully reproduced the 
catalytic properties of MAO B and provided evidence for proton abstraction after an initial 
charge transfer facilitated by a tyrosyl radical cation (Murray et al., 2015), but the system is 
an artificial one that would not necessarily follow the mechanism optimized in the protein. 
Independently of the experimental approaches, theoretical chemistry can now address 
the question of catalytic mechanism using novel computational methods that allow 
consideration of the atoms involved in the chemistry at the most precise level and the 
surrounding protein at a lower level of detail. Using different methods, two computational 
approaches support either the polar nucleophilic (Abad et al., 2013) or the hydride ion 
transfer (Vianello et al., 2012, Repic et al., 2014). The hydride ion transfer mechanism 
gives the lowest activation energy making it the most likely pathway, but better 
experimental evidence for the transition states for each calculated mechanism would be 
useful.  
 
5.   Inhibition of MAO B. 
 
5.1   Irreversible and reversible inhibition of MAO B.   
 
The most successful inhibition of MAO B in vivo comes from drugs that inactivate the 
enzyme by covalent attachment. The examples shown in Table 1 illustrate the main 
classes: the hydrazine, acetylenic (propargyl), and cyclopropyl compounds are activated 
by the enzyme itself. The reactive product forms a covalent bond with the enzyme, usually 
to the flavin cofactor (Mitchell et al., 2001, Edmondson et al., 2009, Bonivento et al., 2010, 
Esteban et al., 2014). Activity in the cell is restored only by synthesis of new MAO B, a 
slow process with a half-life of 9 days in rat brain (Youdim and Tipton, 2002). For the best 
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pharmacological effect, MAO B must be more than 90% inhibited (Fowler et al., 2005). The 
recovery of MAO B in human brain was followed using PET, revealing a recovery period of 
about 40 days (Fowler et al., 2005, Fowler et al., 2015). 
 
Table 1.  Drugs that inhibit MAO B.  
Chemical type Example Structure Drug name Selectivity 
Hydrazine Phenelzine 
2-phenylethylhydrazine 
 
Nardil both 
Acetylenic Deprenyl 
(R)-N-methyl-N-(1-phenyl 
propan-2-yl)prop-2-yn-1-amine 
 
Selegiline B 
Cyclo-
propylamine 
Tranylcypromine 
(1R,2S)-2-
phenylcyclopropanamine  
Parnate B>A 
Reversible Lazabemide  
 
Ro 19-6327 
 
B 
 
 
Irreversible inhibition is characterized in vitro by kinetic analysis, or by determining the 
spectrum, mass, and crystal structure of the adduct. Irreversible inhibition is revealed in 
high-throughput kinetic screening of new compounds by a very much lower IC50 after 30 
minutes pre-incubation of the inhibitor with the enzyme compared to the IC50 when 
enzyme is added to the substrate and inhibitor at the same time. Deeper investigation will 
determine the time course of the inactivation (to measure kinact for chemical reactions or 
the kinetic parameters KI and kinact for mechanism-based inhibitors) and the stability of the 
adduct to dilution or washing the membranes (for example, (Esteban et al., 2014)). The 
mass and structures of the adducts formed have been reported for some 
cyclopropylamines including TCP (Mitchell et al., 2001, Bonivento et al., 2010) and for 
several propargyl compounds (Hubalek et al., 2004, Esteban et al., 2014). The crystal 
structure for rasagiline, a MAO B inhibitor designed for PD, clearly shows the adduct 
attached to N5 of the flavin (Binda et al., 2005b). 
 
Reversible inhibition is apparently simpler. High affinity for the MAO B active site is 
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expressed as a nanomolar Ki in steady-state kinetics. However, the doses required to 
maintain 90% inhibition in competition with the endogenous substrates may make these 
reversible inhibitors less useful for drug administration. Only labazemide, with a nanomolar 
Ki as a result of the slow dissociation of its complex with MAO B, along with moclobemide 
for MAO A have been used in the clinic. Many medicinal chemistry groups are nonetheless 
pursuing the search for a high affinity reversible inhibitor for MAO B. The chemical families 
and lead structures had been reviewed recently (Carradori and Silvestri, 2015).  
 
5.2  Multi-target drugs 
 
Methodical structure-based drug design with experimental screening against several 
targets is being used to generate promising MTDL candidates for the treatment of complex 
neurological diseases such as PD and AD. MAO B inhibition is a key part of molecules 
such as rasagiline used for PD (McCormack, 2014) and in trials for AD. For example, 
ladostigil combines part of rivastigmine to inhibit acetylcholinesterase with rasagiline to 
inhibit MAO (Geldenhuys and Van der Schyf, 2013). An added benefit is the 
neuroprotective effect seen with most propargyl compounds, although it is thought to be a 
non-MAO related effect of the propargyl moiety (Naoi and Maruyama, 2010). The question 
of how neuroprotection is achieved is currently being investigated, with new possible 
influences such as interaction with pro- and anti-apoptotic pathways (Zheng et al., 2005, 
Hara et al., 2006, Naoi et al., 2013, Wu et al., 2015).  
 
One source of oxidative stress is the increased iron present in AD brains (Zecca et al., 
2004).  The brain-permeable M30, combines multiple features including an iron chelator 
and a MAO inhibitor (Youdim, 2006, Kupershmidt et al., 2012, Youdim, 2013). M30 
irreversibly inhibits both MAO A and B with IC50 values of 0.037 µM and 0.57 µM 
respectively (Zheng et al., 2005). Taking the M30 molecule further, an 
acetylcholinesterase inhibitor was added, giving M30D, now being characterized for AD 
treatment. M30D is metabolized to M30 by acetylcholinesterase ensuring that the 
chelating activity is released only in the nervous tissue and thus decreasing toxicity in the 
periphery (Zheng et al., 2010). Similar aims to design inhibition of both cholinesterases 
and monoamine oxidases into one compound resulted in PF1901N (Bolea et al., 2014) or 
in aminocoumarins (Farina et al., 2015) both of which also show neuroprotective effects. 
Other newer MTDL with MAO B inhibition profiles include tacrine-coumarin hybrids (Xie et 
al., 2015) and hydroxyl-quinoline hybrids (Wang et al., 2014). Combinations that target 
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MAO in combination with receptors have also begun to appear (Stoessel et al., 2013, 
Nikolic et al., 2015). 
 
6. Concluding remarks 
 
MAO B inhibition has proven in vivo influence over amine metabolism and behavior. MAO 
B inhibition has anti-depressant activity and spares dopamine in PD. While the gold 
standard for measuring inhibition of MAO B in the brain is PET scanning, platelet activity 
remains a useful, cheaper alternative for investigation of variations in MAO B activity that 
arise not from neurodegeneration but from genetic causes. The association of low MAO B 
activity with predisposition to addiction is supported by some studies, but only the MAO A 
epigenetic pattern has been identified as associated with addiction (Philibert et al., 2010).  
The increase of MAO B activity in ageing brain resulting in increased oxidative stress 
suggests that the hunt for new effective brain-targeted MAO B inhibitors will continue. 
Although new reversible inhibitors have been designed, there is no indication that they will 
be successful in vivo. In the meantime, the traditional irreversible inhibitors are effective 
and well understood drugs. 
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